A
Alessandra Mangia
Researcher at Casa Sollievo della Sofferenza
Publications - 275
Citations - 16068
Alessandra Mangia is an academic researcher from Casa Sollievo della Sofferenza. The author has contributed to research in topics: Hepatitis C & Ribavirin. The author has an hindex of 52, co-authored 249 publications receiving 14911 citations. Previous affiliations of Alessandra Mangia include National Institutes of Health & Catholic University of the Sacred Heart.
Papers
More filters
Journal ArticleDOI
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz,Alessandra Mangia,David L. Wyles,Maribel Rodriguez-Torres,Tarek Hassanein,Stuart C. Gordon,Michael Schultz,M. Davis,Zeid Kayali,K. Rajender Reddy,Ira M. Jacobson,Kris V. Kowdley,L. Nyberg,G. Mani Subramanian,Robert H. Hyland,Sarah Arterburn,Deyuan Jiang,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Aasim Sheikh,Zobair M. Younossi,Edward Gane +23 more
TL;DR: In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Journal ArticleDOI
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam H. Afdhal,Stefan Zeuzem,Paul Y. Kwo,Mario Chojkier,Norman Gitlin,Massimo Puoti,Manuel Romero-Gómez,Jean-Pierre Zarski,Kosh Agarwal,Peter Buggisch,Graham R. Foster,Norbert Bräu,Maria Buti,Ira M. Jacobson,G. Mani Subramanian,Xiao Ding,Hongmei Mo,Jenny C. Yang,Phillip S. Pang,William T. Symonds,John G. McHutchison,Andrew J. Muir,Alessandra Mangia,Patrick Marcellin +23 more
TL;DR: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection.
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Jordan J. Feld,Ira M. Jacobson,Christophe Hézode,Tarik Asselah,Peter Ruane,Norbert Gruener,Armand Abergel,Alessandra Mangia,Ching-Lung Lai,Henry Lik Yuen Chan,Francesco Mazzotta,Christophe Moreno,Eric M. Yoshida,Stephen D. Shafran,William J. Towner,Tram T. Tran,John McNally,Anu Osinusi,Evguenia S. Svarovskaia,Yanni Zhu,Diana M. Brainard,John G. McHutchison,Kosh Agarwal,Stefan Zeuzem +23 more
TL;DR: Once-daily sofosbuvir-velpatasvir for 12 weeks provided high rates of sustained virologic response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis.
Journal ArticleDOI
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
Alessandra Mangia,Rosanna Santoro,Nicola Minerva,G.L. Ricci,Vito Carretta,Marcello Persico,Francesco Vinelli,Gaetano Scotto,D. Bacca,Mauro Annese,Mario R. Romano,Franco Zechini,Fernando Sogari,Fulvio Spirito,Angelo Andriulli +14 more
TL;DR: Treatment with peginterferon and ribavirin for 16 weeks in patients infected with HCV genotype 2 or 3 results in a lower overall sustained virologic response rate than treatment with the standard 24-week regimen.
Journal ArticleDOI
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem,Geoffrey Dusheiko,Riina Salupere,Alessandra Mangia,Robert Flisiak,Robert H. Hyland,Ari Illeperuma,Evguenia S. Svarovskaia,D.M. Brainard,William T. Symonds,G. Mani Subramanian,John G. McHutchison,Ola Weiland,Hendrik W. Reesink,Peter Ferenci,Christophe Hézode,Rafael Esteban +16 more
TL;DR: Therapy with sofosbuvir-ribavirin for 12 weeks in patients with hepatitis C virus genotype 2 infection and for 24 weeks in Patients with HCV genotype 3 infection resulted in high rates of sustained virologic response.